Literature DB >> 20718748

Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

A Oros1, M J Houtman, P Neco, A M Gomez, S Rajamani, P Oosterhoff, N J Attevelt, J D Beekman, M A G van der Heyden, L Ver Donck, L Belardinelli, S Richard, G Antoons, M A Vos.   

Abstract

BACKGROUND AND
PURPOSE: The high predisposition to Torsade de Pointes (TdP) in dogs with chronic AV-block (CAVB) is well documented. The anti-arrhythmic efficacy and mode of action of Ca(2+) channel antagonists, flunarizine and verapamil against TdP were investigated. EXPERIMENTAL APPROACH: Mongrel dogs with CAVB were selected based on the inducibility of TdP with dofetilide. The effects of flunarizine and verapamil were assessed after TdP and in different experiments to prevent dofetilide-induced TdP. Electrocardiogram and ventricular monophasic action potentials were recorded. Electrophysiological parameters and short-term variability of repolarization (STV) were determined. In vitro, flunarizine and verapamil were added to determine their effect on (i) dofetilide-induced early after depolarizations (EADs) in canine ventricular myocytes (VM); (ii) diastolic Ca(2+) sparks in RyR2(R4496+/+) mouse myocytes; and (iii) peak and late I(Na) in SCN5A-HEK 293 cells. KEY
RESULTS: Dofetilide increased STV prior to TdP and in VM prior to EADs. Both flunarizine and verapamil completely suppressed TdP and reversed STV to baseline values. Complete prevention of TdP was achieved with both drugs, accompanied by the prevention of an increase in STV. Suppression of EADs was confirmed after flunarizine. Only flunarizine blocked late I(Na). Ca(2+) sparks were reduced with verapamil. CONCLUSIONS AND IMPLICATIONS: Robust anti-arrhythmic efficacy was seen with both Ca(2+) channel antagonists. Their divergent electrophysiological actions may be related to different additional effects of the two drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718748      PMCID: PMC2962825          DOI: 10.1111/j.1476-5381.2010.00883.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.

Authors:  Gudrun Antoons; Avram Oros; Jet D M Beekman; Markus A Engelen; Marien J C Houtman; Luiz Belardinelli; Milan Stengl; Marc A Vos
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

2.  Protective activity of calcium entry blockers against ouabain intoxication in anesthetized guinea pigs.

Authors:  F A Jonkman; H W Boddeke; P A van Zwieten
Journal:  J Cardiovasc Pharmacol       Date:  1986 Sep-Oct       Impact factor: 3.105

3.  Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia.

Authors:  S G Priori; C Napolitano; N Tiso; M Memmi; G Vignati; R Bloise; V Sorrentino; G A Danieli
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  Effects of tetrodotoxin, lidocaine, verapamil, and AHR-2666 on Ouabain-induced delayed afterdepolarizations in canine Purkinje fibers.

Authors:  M R Rosen; P Danilo
Journal:  Circ Res       Date:  1980-01       Impact factor: 17.367

6.  Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness.

Authors:  S M Pogwizd; K Schlotthauer; L Li; W Yuan; D M Bers
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

Review 7.  Assessing predictors of drug-induced torsade de pointes.

Authors:  Luiz Belardinelli; Charles Antzelevitch; Marc A Vos
Journal:  Trends Pharmacol Sci       Date:  2003-12       Impact factor: 14.819

8.  Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.

Authors:  Morten B Thomsen; S Cora Verduyn; Milan Stengl; Jet D M Beekman; Geert de Pater; Jurren van Opstal; Paul G A Volders; Marc A Vos
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

9.  Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle.

Authors:  E Marban; S W Robinson; W G Wier
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

10.  Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers.

Authors:  P A van Zwieten
Journal:  Eur Neurol       Date:  1986       Impact factor: 1.710

View more
  11 in total

1.  Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations.

Authors:  Gary Gintant
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?

Authors:  Thom R G Stams; Vincent J A Bourgonje; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.

Authors:  Shashank Gupta; Sandeep Tyagi; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

4.  The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs.

Authors:  T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  The high frequency relationship: implications for torsadogenic hERG blockers.

Authors:  P Champeroux; J Y Le Guennec; S Jude; C Laigot; A Maurin; M L Sola; J S L Fowler; S Richard; J Thireau
Journal:  Br J Pharmacol       Date:  2016-01-14       Impact factor: 8.739

6.  Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations.

Authors:  P Champeroux; J Thireau; S Judé; C Laigot-Barbé; A Maurin; M L Sola; J S L Fowler; S Richard; J Y Le Guennec
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

Review 7.  Short-term Variability of Repolarization Is Superior to Other Repolarization Parameters in the Evaluation of Diverse Antiarrhythmic Interventions in the Chronic Atrioventricular Block Dog.

Authors:  Alexandre Bossu; Rosanne Varkevisser; Henriette D M Beekman; Marien J C Houtman; Marcel A G van der Heyden; Marc A Vos
Journal:  J Cardiovasc Pharmacol       Date:  2017-06       Impact factor: 3.105

8.  Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.

Authors:  Anne-Françoise Schlit; Annie Delaunois; Aurore Colomar; Branderley Claudio; Luca Cariolato; Rossen Boev; Jean-Pierre Valentin; Christopher Peters; Victor S Sloan; Jürgen W G Bentz
Journal:  Pharmacol Res Perspect       Date:  2017-04-21

Review 9.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

10.  Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia.

Authors:  Alexandre Bossu; Marien J C Houtman; Veronique M F Meijborg; Rosanne Varkevisser; Henriette D M Beekman; Albert Dunnink; Jacques M T de Bakker; Nevena Mollova; Sridharan Rajamani; Luiz Belardinelli; Marcel A G van der Heyden; Marc A Vos
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.